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ABSTRACT:
miR-155 is an oncogenic microRNA which is upregulated in many solid cancers. 
The targets of miR-155 are well established , with over 100 confirmed mRNA targets. 
However, the regulation of miR-155 and the basis of its upregulation in cancer is not 
well understood. We have previously shown that miR-155 is regulated by p63, and here 
we investigate the role of the major p63 isoforms TAp63 and ΔNp63 in this regulation. 
When the TAp63 isoform was knocked down, or exogenously overexpressed, miR-
155 levels were elevated in response to TAp63 knockdown or reduced in response 
to TAp63 overexpression. The ΔNp63 isoform is shown to directly bind to the p63 
response element on the miR-155 host gene, and this binding is enriched when TAp63 
is knocked down. This could indicate that TAp63 prevents ΔNp63 from binding to 
the miR-155 host gene. The knockdown of TAp63, and the subsequent elevation of 
miR-155, enhances migration and tumour growth similar to that seen when directly 
overexpressing miR-155. The migratory phenotype is abrogated when miR-155 is 
inhibited, indicating that miR-155 is responsible for the phenotypic effect of TAp63 
knockdown.
INTRODUCTION
MicroRNAs (miRs) are short noncoding RNAs that 
fine-tune gene regulation by inhibiting translation of their 
target mRNAs [1]. A single miR can regulate many target 
genes through specific binding to short seed sequences 
generally located in a gene’s 3’ untranslated region (UTR).
Due to their ability to regulate many genes in 
multiple different pathways, aberrant expression of a miR 
can have severe consequences.  miR-155 is an oncogenic 
miR upregulated in multiple cancers including leukaemia, 
lymphoma, colon, thyroid, pancreatic, gastric, lung and 
breast cancer [2-5]. Elevated miR-155 expression is 
associated with poor prognosis in pancreatic and lung 
cancers [6, 7], while in breast cancers miR-155 expression 
contributes to epithelial cell plasticity as well as driving 
invasion [8, 9]. Other miRs can have an opposite, tumour 
suppressive, role such as miR-218 inhibiting cell migration 
and invasion [10].
The downstream targets of miR-155 are well 
established with over one hundred validated [11]. These 
mRNA targets are involved in a number of diverse 
pathways. For example, miR-155 has been shown to 
regulate the angiogenesis promoter HIF-1α [12], the 
apoptosis factors FADD and CASP3 [13], and members of 
the SMAD family of genes which are involved in epithelial 
to mesenchymal transition (EMT) [14-16].
However, the mechanisms by which miR-155 is 
upregulated in cancer is not understood, as the pathways 
regulating miR-155 expression have not been fully 
explored. miR-155 is encoded by the BIC (also known 
as MIR155) gene [17], a spliced and adenylated but non-
protein coding gene that was originally implicated in 
lymphoma [18]. There is data relating to the regulation 
of miR-155 in the immunological setting where miR-
155 is regulated by cytokines, interleukins and interferon 
such as ERK/JNK [14] and STAT1 [19]. The basis for 
the upregulation of miR-155 in cancer is unknown.  In 
breast cancer it has been shown that the TGF-β epithelial-
mesenchymal transition pathway upregulates miR-155 
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through SMAD4 [8]. Additionally, BRCA1 has been 
shown to epigenetically repress the expression of miR-
155[20], and this repression can be lost in breast cancer 
[21]. Epigenetic repression of  another miR, miR-211, has 
been shown to control apoptosis, chemosensitivity and 
radiosensitivity in glioma [22], therefore the regulation 
of miR-155 may be similarly significant. Recently, in 
colon cancer miR-155 expression was shown to be 
promoted by S100P/RAGE through Activator Protein-1 
(AP-1) stimulation [23]. In other solid cancers the exact 
mechanisms of miR-155 upregulation have not been 
reported.
Previously, we showed that miR-155 can be 
repressed by direct binding of either p53 or p63 to 
response elements in the host gene, BIC [9]. p63 is a 
member of the p53 family of transcriptional regulators 
and shares sequence homology with the transactivating, 
DNA binding, and oligomerisation domains of p53. 
While this may suggest a similar role to p53, the 
“guardian of the genome”, it has emerged that p63 is a 
regulator of epithelial development [24, 25]. There are 
two major isoforms of p63, resulting from alternative 
transcriptional start sites. The full-length TAp63 isoform 
contains an N-terminal transactivation domain whereas 
ΔNp63 is a truncated version that lacks this domain [26]. 
Curiously, the two isoforms exert opposing functions in 
cancer with TAp63, similarly to p53, functioning as a 
tumour suppressor and inducing cell death and cell cycle 
arrest [27]. Knockout of TAp63 in mice, results in the 
spontaneous formation of metastatic tumours [28]. In 
contrast, ΔNp63 is oncogenic and often overexpressed in 
cancer [29]. 
It is not known which of the p63 isoforms mediates 
the regulation of miR-155 expression. This study 
investigates the role of p63 isoforms in the regulation 
of miR-155 expression and the resulting phenotypic 
consequences. 
RESULTS
The expression of miR-155 is regulated by TAp63
In order to investigate the regulation of miR-
155 expression by the p63 isoforms, isoform specific 
knockdowns were created in two cell lines using a 
Figure 1: Knockdown of TAp63 induces miR-155 expression. MCF10A breast epithelial cells and A431 skin carcinoma cells were 
transduced with shRNAs targeting TAp63, total p63 (2 independent shRNAs) or a non-silencing control shRNA (SCR). A, B: p63 isoform 
RNA expression levels of MCF10A and A431 knockdown cell lines were measured using isoform-specific qRT-PCR. C, D: Western blot 
analysis of p63 protein in MCF10A and A431 cells treated with p63 shRNA hairpins. The anti-p63 antibody (H-129) detects both the TAp63 
and ΔNp63 isoforms although both MCF10A and A431 cells contain ~99% ΔNp63 isoform. E, F: Mature miR-155 expression levels of 
MCF10A and A431 cells treated with p63 shRNA hairpins were measured using specific Taqman miRNA probes. 
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shRNA approach. The MCF10A breast non-malignant 
epithelial cell line and A431 skin carcinoma cell line were 
selected due to their high endogenous p63 (predominantly 
ΔNp63 isoform) and low miR-155 expression levels 
(Supplementary Figure 1). Three shRNA hairpins 
targeting the p63 transcript and a non-silencing control 
shRNA were used to knock down p63 expression in these 
cell lines, with one p63 shRNA selectively targeting the 
TAp63 isoform and two independent shRNAs targeting 
both isoforms. Unfortunately we were not able to create 
a ΔNp63 specific knockdown. Knockdown was measured 
by isoform-specific real-time qPCR (Figure 1A, B) and by 
western blot (Figure 1C, D). TAp63 protein is expressed 
at a level undetectable by western blot in these cells 
but qPCR showed the specific shRNA hairpin reduced 
expression of the TAp63 isoform in MCF10A cells by 
85% and in A431 cells by 50%.  .
The expression level of mature miR-155 was 
measured by real-time qPCR using specific Taqman 
probes. In MCF10A cells, miR-155 expression levels 
increased by over six-fold when TAp63 was knocked 
down (Figure 1E). Similar results were observed in A431 
cells where the TAp63 knockdown resulted in a six-fold 
increase in miR-155 expression (Figure 1F). The lack of 
influence of knockdown of the ΔNp63 isoform (up to 90% 
in MCF10A and 60% in A431) on MIR155 expression 
implies a specific repressive role of the full-length isoform 
of p63 on MIR155 expression.
Exogenous expression of TAp63 inhibits miR-155 
expression
To further investigate the role of p63 isoforms on 
MIR155 expression, the two p63 isoforms were each 
over-expressed in the BT549 breast tumour cell line, 
which endogenously expresses a high level of miR-
155 (Supplementary Figure 1) and low endogenous 
p63. miR-155 expression levels, analysed by real-time 
qPCR (Figure 2), were significantly decreased by over-
expression of TAp63, while over-expression of ΔNp63 
did not significantly change miR-155 expression levels. 
Therefore both knockdown and over-expression of TAp63 
isoforms are consistent with the TAp63 isoform having a 
repressive regulatory effect on miR-155 expression levels.
The ΔNp63 isoform directly binds the miR-155 
p63RE and drives expression
Previously we showed that p53 and p63 bind to the 
response element present in exon 3 of the miR-155 host 
gene (MIR155 or BIC, schematic diagram shown in Figure 
3A)[9]. To determine which p63 isoform was binding at 
this site, p63 ChIP assays were completed on H1299 cells 
exogenously expressing either TAp63 or ΔNp63 (Figure 
3B). Binding at the p63-RE was enriched when the 
ΔNp63 isoform was expressed in these cells, while in cells 
exogeneously expressing the TAp63 isoform there was no 
significant difference between TAp63 binding and vector 
control. To explore this further, p63 ChIP assays used 
MCF10A cells with either the TAp63 isoform, or total 
p63 expression, knocked down with shRNAs (Figure 3C). 
Binding of p63 to the MIR155 p63 response element was 
enriched in the TAp63 specific knockdown, as compared to 
the IgG and SCR control. Together these two approaches 
are consistent with ΔNp63 binding to the response element 
on MIR155. This was unexpected considering the previous 
findings showing a specific repressive effect of only the 
TAp63 isoform on the expression of miR-155.
In order to confirm that ΔNp63 has an effect on 
the miR-155 p63 response element and is able to drive 
expression of miR-155, the ability of the p63 isoforms 
to drive expression of a luciferase reporter gene was 
assessed in 293T cells. The ΔNp63 isoform was able 
to drive luciferase activity through the miR-155 p63 
response element, as compared to empty luciferase vector 
and mutant response element (Figure 3D). The luciferase 
activity of TAp63 was not significantly different between 
wildtype and mutant response element, indicating that it is 
the ΔNp63 isoform that is acting upon the miR-155 host 
gene p63 response element.Figure 2: Exogenous expression of TAp63 inhibits 
miR-155 expression. TAp63, ΔNp63 or empty vector 
were transiently transfected into BT549 breast tumour cells. 
Expression levels of MIR155 mRNA levels were measured 
by real-time qPCR. p63 isoform expression in these cells was 
validated using western blot. 
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Release of miR-155 from TAp63 regulation drives 
migration 
To investigate the relative contribution of miR-
155 to the biological role of p63 as a tumour suppressor, 
the expression of miR-155 and p63 were modulated in 
MCF10A and A431 cells. 
The migratory abilities of MCF10A and A431 
cells with either TAp63 knockdown or miR-155 
overexpression were determined using a scratch wound 
assay (Figure 4). The miR-155 levels following TAp63 
knockdown were comparable to the levels seen with 
miR-155 overexpression cells (Supplementary Figure 2). 
TAp63 knockdown, or miR-155 over-expression, both 
increased the migratory potential of MCF10A and A431 
cells (4A, C). In a “rescue treatment” of both cells lines 
use of anti-miR-155 inhibited this migratory phenotype, 
indicating that this phenotype is dependent on miR-155. 
Total p63 knockdown had no effect on migration (4D, 
Supplementary Figure 3). These data suggest that the 
increase in migratory potential resulting from TAp63 
knockdown is largely caused by the resulting increase in 
miR-155 expression.
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Figure 3: ΔNp63 binds to the miR-155 host gene and drives expression. A: The p63 response element and miR-155 ncRNA are 
located in exon 3 of the miR-155 host gene. B, C: ChIP assays were performed in H1299 cells transfected with TAp63, ΔNp63 or empty 
vector overexpression constructs (B) and in MCF10A cells with p63 isoforms knocked down by shRNA (C). DNA–p63 complexes were 
immunoprecipitated from samples using a p63 antibody (or IgG control). Fold enrichment of binding to the p63-RE within the MIR155HG 
gene was determined as compared to IgG controls. Protein expression of p63 isoforms in the H1299 cell lysate was determined using 
western blot. D: Dual luciferase reporter assay of empty pGL3 Basic vector, pGL3-p63RE or pGL3-mutantp63RE co-transfected with 
pRL-TK and either empty vector, TAp63 or ΔNp63. 
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TAp63 knockdown and miR-155 overexpression 
enhance tumour growth
The effect of TAp63, total p63 knockdown, and miR-
155 overexpression on tumour growth was analysed in a 
xenograft model where modified A431 cells were injected 
subcutaneously into Balb/C nude mice, and the tumour 
volume monitored over 3 to 5 weeks. A431 cells (and 
not MCF10A cells) were selected due to their previous 
established tumourigenicity in xenograft studies [30]. 
TAp63 knockdown enhanced tumour growth, compared 
with both control and total p63 knockdown (Figure 5A), 
where after 3 weeks the average tumour volume of mice 
bearing TAp63 knockdown was approximately twice 
that of the total p63 knockdown and control groups. 
The overexpression of miR-155 also enhanced tumour 
growth, but there was greater variation within the miR-
155 overexpression and control groups (Figure 5C). This 
suggests that the effect of TAp63 knockdown on tumour 
growth is at least partly attributable to the resulting 
increase in miR-155 expression.
Figure 4: Release of miR-155 from TAp63 regulation drives migration. A,B: The ability of MCF10A or A431 SCR, TAp63KD, 
miR control and miR-155 overexpressing cells to migrate with application of anti-miR-155 inhibitor (+) or a non-targeting anti-miR (-) was 
determined by a scratch-wound assay. Wound width was calculated using Incucyte software. C, D: Representative real time wound width 
data for SCR, TAp63KD (C) and total p63KD (D).
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DISCUSSION
It has been observed that miR-155 is up-regulated 
in numerous solid cancers [2-5] but the mechanism by 
which this occurs is not well understood. Previously we 
showed that MIR155 is under the regulation of p63 [9]. 
Here we show for the first time the effect of individual p63 
isoforms on miR-155 expression.
p63 isoforms, and the ratios between their 
expression, have been shown to have a role in cancer [31]. 
The full-length TAp63 isoform is a tumour suppressor [27], 
so it would be expected to suppress miR-155 expression. 
Conversely, ΔNp63 has oncogenic effects [29] and would 
be expected to drive or enhance miR-155 expression. In 
two separate epithelial cell lines, knockdown of the TAp63 
isoform greatly induced miR-155 expression, while total 
p63 knockdown had little or no effect (Figure 1). This 
indicates that miR-155 is under the regulation of TAp63 
in some way, either directly or indirectly. In light of miR 
regulation TAp63 is known to transactivate DICER and 
thus miRs in general [28]. The findings presented here are 
not a result of aberrant DICER expression, as when TAp63 
is knocked down (hence reducing DICER transactivation 
by TAp63) global miR biogenesis would be expected to be 
reduced along with DICER protein levels. Contrary to this, 
miR-155 expression levels increase as shown in Figure 1.
Consistent with these findings, exogenous 
expression of the TAp63 isoform caused miR-155 
expression levels to decrease. Overexpression of the 
ΔNp63 isoform had no effect on miR-155 (Figure 2). 
These results indicate that TAp63 acts as a tumour 
suppressor and inhibits miR-155 expression.
Thus, it was unexpected that the ΔNp63 isoform, 
and not TAp63, bound directly to the p63 response element 
on the miR-155 host gene, as shown by ChIP assay of the 
miR-155 host gene p63 response element. On the basis 
of the results from both knockdown and overexpression 
of each isoform it would be predicted that TAp63 binds 
to the miR-155 host gene and suppresses its expression. 
However, the ChIP assays show ΔNp63 binding to the 
response element on MIR155, and that binding is enriched 
when TAp63 is knocked down (Figure 3). We speculate 
that when TAp63 is present, ΔNp63 is unable to bind to 
the miR-155 host gene. When TAp63 is removed, ΔNp63 
can bind to the miR-155 host gene and drive expression 
as shown by luciferase assay (Figure 3). This is consistent 
with the observations in TAp63 knockdown cells that 
p63 binding to MIR155 is enriched, and miR-155 levels 
Figure 5: TAp63 knockdown and miR-155 overexpression enhance tumour growth. A: A431 cells bearing TAp63 knockdown, 
total p63 knockdown or scrambled control were xenografted into nude mice, and the tumour volume measured for up to 36 days. B: Mature 
miR-155 levels of snap frozen xenograft tumours, analysed by miR-155 specific probe and compared to miR-16. C: A431 cells bearing 
miR-155 overexpression or a miR control were xenografted into nude mice, and the tumour volume measured for up to 23 days. D: Mature 
miR-155 levels of snap frozen xenograft tumours, analysed by miR-155 specific probe and compared to miR-16.
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are increased. This does seem to be conflicting with 
the finding that overexpression of ΔNp63 had no effect 
on miR-155 levels in BT549 cells (Figure 2), however 
miR-155 is already expressed at such a high level in this 
particular cell line [9] that any inductive effect of  ΔNp63 
is not displayed in this cell line.
Does the induction of miR-155 expression caused 
by the release from TAp63 regulation have any functional 
effect? To answer this question we performed scratch 
wound assays comparing the migratory potential of the 
TAp63 knockdown cells (indirectly overexpressing miR-
155) with cells overexpressing miR-155 directly. Both 
TAp63 knockdown and miR-155 overexpression showed 
a significant increase in migration (Figure 4), indicating 
that miR-155, when released from TAp63 regulation, can 
drive migration. Further, in the presence of anti-miR-155 
this phenotype was inhibited. This shows that it is the 
elevated expression of miR-155 that is the major driver of 
the phenotype resulting from TAp63 knockdown. 
In a mouse xenograft model using the A431 cell 
line, both TAp63 knockdown and miR-155 overexpression 
enhanced tumour growth, while total p63 knockdown had 
no effect (Figure 5). Interestingly, TAp63 knockdown 
takes effect gradually on tumour growth and increases 
over time, whereas miR-155 overexpressing tumours have 
a significant (p<0.01) initial surge of growth early on with 
subsequent growth resulting in no significant difference 
from the scramble control. Despite this difference, both 
groups reach an average tumour volume of approximately 
400 at day 21. This difference in growth dynamics 
could be due to a number of factors. It could be caused 
by variation between batches of animals used for the 
xenograft. Alternatively, it could be the impact of TAp63 
knockdown on pathways other than those influenced by 
miR-155. Also of note is that the miR-155 levels in the 
miR-155 overexpression group are higher than in the 
TAp63 knockdown group even though the cell lines prior 
to the xenograft contained similar levels of miR-155. This 
could suggest a positive selection within the xenograft for 
cells overexpressing miR-155, consistent with miR-155’s 
function as an antimiR. Alternatively, signals from the host 
animal might have interfered with the p63 interaction with 
the miR-155 host gene in some way that did not affect 
the direct miR-155 overexpressing cells. Regardless, the 
increased xenograft tumour growth in cells with TAp63 
knockdown and miR-155 overexpression is consistent 
with miR-155 being a major contributor to the oncogenic 
phenotype driven by p63.
We therefore present a mechanism whereby TAp63 
suppresses miR-155 expression and when this regulation 
is removed, ΔNp63 is able to drive miR-155 expression 
and thus migration and tumorigenesis. This mechanism 
is reflective of both the oncogenic properties of ΔNp63, 
and the tumour suppressor role of TAp63 [27, 29]. In 
addition, the ΔNp63 isoform is the most expressed 
isoform in many cancers [32], which may be linked to 
miR-155 being upregulated in many solid cancers [2-5]. 
The oncogenic effects of TAp63 knockdown are in line 
with the documented oncogenic role of miR-155 [6-8], 
and the attenuation of this effect by the anti-miR-155 
antimiR indicate that the functional effect caused by 
TAp63 knockdown is mediated largely by miR-155. 
Further, the increased migration potential caused by 
TAp63 knockdown supports previous studies linking p63 
to migration, where a microarray of p63-siRNA-treated 
squamous cell carcinoma showed the upregulation of 
multiple cell motility genes [33], and TAp63 regulates 
miR-205 which is linked to cell migration in prostate 
cancer [34].
As the two p63 isoforms are known to directly 
interact [35, 36], this provides a possible mechanism of the 
unexpected enrichment of ΔNp63 binding to the response 
element on the miR-155 host gene when TAp63 is 
knocked down. Although it is usually the ΔNp63 isoform 
that exerts a dominant negative effect on TAp63 [31], it is 
also possible that TAp63 could have a negative effect on 
ΔNp63 action. The final member of the p53 family is p73. 
It is possible that p73 is also involved in this pathway, 
as it has been shown that p63-regulated miRs other than 
miR-155 have been linked to p73, inhibiting its ability 
to promote genetic stability and chemosensitivity [37]. 
Exploring the relationship between miR-155 and p73 
might be a valuable path for future research.
These results provide a potential mechanism for our 
previous findings that miR-155 expression is upregulated 
in the presence of mutant p53 [9], as mutant p53 interacts 
with and inhibits the action of p63 isoforms, in particular 
TAp63 [38-40]. Further, mutant p53 has been shown to use 
p63 as a molecular chaperone to promote the expression 
of target genes and induce invasion [41]. In this instance 
mutant p53 might be using the ΔNp63 isoform as a 
chaperone to drive a migratory phenotype. In the future 
the relationship between the p63 isoforms, mutant p53 
and miR-155 should be investigated to reveal the full 
mechanism of miR-155 upregulation in cancer.
MATERIALS AND METHODS
Expression constructs
pMSCV-Puro-GFP , pMSCV-Puro-GFP-miR-155 – 
kindly donated by Erik Flemington TAp63-specific shRNA 
oligonucleotide (V2LHS24249), total p63 targeting 
shRNA (V2LHS24246 and V3LHS397885), non-silencing 
control (RHS4346) – Thermo Scientific pcDNA3.1-
TAp63-HA, pcDNA3.1-ΔNp63-myc, pcDNA3.1 vehicle 
– kindly donated by Patricia Muller
Oncotarget 2013; 4:1901www.impactjournals.com/oncotarget
Cell culture
MCF10A cells were maintained in Dulbecco’s 
modified Eagle’s medium F12, supplemented with 5% 
horse serum, 20ng/mL epidermal growth factor (R&D 
Systems), 0.5µL/mL hydrocortisone (Sigma), 100ng/mL 
cholera toxin (Sigma) and 10µg/mL insulin (Promega). 
A431 and H1299 cells were maintained in DMEM 
supplemented with 10% foetal calf serum (FCS). BT549 
cells were maintained in RPMI supplemented with 10% 
FBS.
For constitutive knockdown of p63 isoforms, 
TAp63-specific shRNA oligonucleotide (V2LHS24249) 
total p63 targeting shRNA (V2LHS24246 and 
V3LHS397885) or a non-silencing control (RHS4346) 
was used in accordance with the manufacturer’s protocol 
(Open Biosystems).
For exogenous expression of p63 isoforms, 1 µg 
of pcDNA3.1 vehicle control, pcDNA3.1-TAp63-HA or 
pcDNA3.1-ΔNp63-myc was transfected using lipitoid 
transfection reagent following the manufacturer’s protocol 
[42]. 
MCF10A and A431 cells were engineered to express 
either miR-155 or a non-targeting SCR control through 
retroviral mediated transduction with viruses generated 
by the pMSCV-Puro-GFP-miR-155 or pMSCV-Puro-GFP 
vectors according to manufacturer’s instructions, followed 
by selection in 1µg/mL puromycin (Sigma-Aldrich, Castle 
Hill, NSW, Australia).
Isolation of RNA, reverse-transcription (RT–
PCR) and microRNA analysis
Briefly, total RNA was extracted from cells using 
Trizol (Invitrogen), with quantitative real-time PCR 
performed as previously described [9]. Specific primers for 
real-time PCR are listed in Supplementary Table 1. Mature 
miR-155 measurements were made using the ABI Taqman 
miRNA assay for miR-155 following the manufacturer’s 
protocol. Mature miR-155 levels were normalized using 
the average expression levels of housekeeper miR-16.
Western blot analysis and ChIP
Western blot analysis was performed as previously 
described [43], using rabbit α-p63 H-129 (Santa Cruz) 
and mouse α-β actin (Sigma Aldrich). ChIP analysis was 
performed as previously described [9].
Luciferase assay
The wildtype or mutant miR-155 p63 response 
element was cloned into the pGL3 basic luciferase vector 
(Promega). Primers used for cloning the response element 
are listed in Supplementary Table 1. The luciferase 
vector was then transfected into 293T cells using lipitoid 
transfection reagent according to the manufacturer’s 
protocol [42] along with 5 ng of pcDNA3.1 vehicle 
control, pcDNA3.1-TAp63-HA or pcDNA3.1-ΔNp63-myc 
and 20ng of pRL-TK. The assay was carried out using the 
Promega Dual Luciferase Reporter Assay System kit, 
using 20 uL of the LARII and Stop&Glo reagents and 
following the manufacturer’s instructions. Ratio of firefly 
to renilla luciferase was measured using a Glomax 20/20 
luminometer. Reactions were carried out in duplicate, and 
each well was measured twice to ensure correct reading.
Migration assay
Cell migration was analysed by measuring the width 
of a scratch wound in real time using Incucyte (Essen, MI, 
USA). Phase contrast images were taken every 30 min or 
1 hour and wound closure and cell confluence calculated 
using Incucyte software. For antimiR inhibition of miR-
155, miRvana miR-155 inhibitor (Life Technologies) or a 
negative control was transfected using lipitoid transfection 
reagent following the manufacturer’s protocol [42]. 
Xenograft
Stably infected cells (5x105 cells per animal) were 
suspended in 100uL of DMEM serum free medium, 
mixed with 100µL of 10% Matrigel (BD) and injected 
subcutaneously into 5-8 week old female BALB/c nude 
mice. Tumour size was measured twice weekly using 
callipers. Animals were humanely euthanized after 3-5 
weeks depending on tumour volume. The tumour was snap 
frozen and RNA extracted for miR-155 measurement by 
specific Taqman probe. Animal protocols were approved 
by the ethics committee of University of Adelaide and 
IMVS. 
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